Lineage Cell Therapeutics Inc. — Director's Dealing 2021

Jul 4, 2021

F ORM 4
---------------	--

[ ] Check this box if no longer subject to Section 16. Form 4 or continue. See Instruction 1(b).

FORM 4 Washington, D.C. 20549

OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

Form 5 obligations may UNITED STATES SECURITIES AND EXCHANGE COMMISSION STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES OMB APPROVAL

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person *	2. Issuer Name and Ticker or Trading Symbol	5. Relationship of Reporting Person(s) to Issuer
		(Check all applicable)
BRADSHER NEAL C	Lineage Cell Therapeutics, Inc. [ LCTX ]
(Last) (First) (Middle)	3. Date of Earliest Transaction (MM/DD/YYYY)	X Director X 10% Owner
		_ Officer (give title below) ___ Other (specify below)
C/O BROADWOOD CAPITAL	7/1/2021
INC., 142 WEST 57TH STREET, 11TH
FLOOR
(Street)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line)
NEW YORK, NY 10019 (City) (State) (Zip)		_X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security	2. Trans. Date	2A. Deemed	3. Trans. Code			4. Securities Acquired (A)		5. Amount of Securities Beneficially Owned	6.	7. Nature
(Instr. 3)		Execution	(Instr. 8)		or Disposed of (D)			Following Reported Transaction(s)	Ownership	of Indirect
		Date, if any			(Instr. 3, 4 and 5)			(Instr. 3 and 4)	Form:	Beneficial
									Direct (D)	Ownership
									or Indirect	(Instr. 4)
						(A) or			(I) (Instr.
			Code	V	Amount	(D)	Price		4)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		Expiration Date	6. Date Exercisable and	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following	10. Ownership Form of Derivative Security: Direct (D)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Reported Transaction(s) (Instr. 4)	or Indirect (I) (Instr. 4)
OPTION TO PURCHASE COMMON SHARES	\$2.86	7/1/2021		A		50000		(1)	7/1/2031	COMMON SHARES	50000	(2) \$0	50000	D
OPTION TO PURCHASE COMMON SHARES	\$0.8263							(3)	7/1/2030	COMMON SHARES	40000		40000	D
OPTION TO PURCHASE COMMON SHARES	\$1.03							(3)	6/30/2029	COMMON SHARES	40000		40000	D
OPTION TO PURCHASE COMMON SHARES	\$1.67							(3)	6/30/2023	COMMON SHARES	49440		49440	D
OPTION TO PURCHASE COMMON SHARES	\$2.55							(3)	6/30/2022	COMMON SHARES	24720		24720	D

Explanation of Responses:

• (1) These options will vest and become exercisable on July 1, 2022, provided, that Neal C. Bradsher (the "Reporting Person") remains a member of the board of directors of Lineage Cell Therapeutics, Inc. (the "Issuer") on that date.
• (2) These options were granted to the Reporting Person by the Issuer on July 1, 2021 as director compensation pursuant to the Issuer's 2012 Equity Incentive Plan, as amended.
• (3) These options are currently exercisable.

Reporting Owners

Reporting Owner Name / Address		Relationships
	Director	10% OwnerOfficerOther
BRADSHER NEAL C

Signatures

/s/ Neal C. Bradsher	7/1/2021
**Signature of Reporting Person	Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.